It has confirmed that high expression of CCL22 is related to a better prognosis in patients with colon cancer, and CCL22 as a prognostic DEG is used to construct a cellular senescence-related risk model in colon cancer (Dai et al., 2022b). This evidence concerns the gene CCL22 and malignant colon neoplasm.